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Abstract: Tamarix nilotica (Ehrenb.) Bunge (Tamaricaceae), an indigenous plant to the Middle
East region, is well-known as a medicinal plant for treating many human ailments. The current
study aimed at exploring the polyphenol profile of the alcohol soluble fraction of aqueous
T. nilotica extract, assessing its in vivo antifibrotic activity and the possible underlying mechanism,
to unravel the impact of quantitative difference of sulphated polyphenols content on the antifibrotic
activity of T. nilotca grown in two different habitats. Polyphenol profiling of T. nilotica extracts
was performed using HPLC-HRESI-QTOF-MS-MS. The major polyphenol components included
sulphated flavonoids, phenolic acids and free aglycones. The antifibrotic activity was evaluated
through carbon tetrachloride-induced liver fibrosis in rats. Biochemical evaluations revealed that
both fractions ameliorated the increased levels of hepatic aminotransferases, lipid peroxidation,
hydroxyproline, α-smooth muscle actin (α-SMA), tumor necrosis factor-α (TNF-α), cyclooxygenase-2
(COX-2) and nuclear factor kappa B (NF-κB). Moreover, both fractions reduced catalase activity
(CAT) and enhanced hepatic glutathione (GSH) content. Histopathological imaging undoubtedly
confirmed such results. In conclusion, the T. nilotica polyphenol-rich fraction exhibited potential
antifibrotic activity in rats. Significant alterations in GSH levels were recorded based on the sulphated
polyphenol metabolite content.
Keywords: Tamarix nilotica; Tamaricaceae; polyphenols; HPLC/HRESI/MS/MS; antifibrotic activity
1. Introduction
Hepatic fibrosis is a consequence of chronic liver diseases such as chronic hepatitis C virus (HCV)
infection, alcohol abuse and non-alcoholic steatohepatitis (NASH) [1]. Hepatic fibrosis is characterized
by an excessive accumulation of extracellular matrix (ECM) proteins, including collagen as a common
wound healing response, distorting the normal hepatocellular architecture and forming a fibrous scar,
which subsequently develops into hepatocellular nodules or an irreversible complication known as
liver cirrhosis [2]. In developing and developed countries, liver cirrhosis represents an end-stage liver
complication where liver transplantation becomes the only treatment choice, which is even not easy to
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achieve considering the number of donor organs available and the clinical condition of the potential
recipients [3].
Therefore, research interests have been directed toward hepatic fibrosis several decades ago as
the last reversible phase of complicated chronic hepatic diseases before turning into liver cirrhosis [1].
Based on the inconsistent effectiveness of treatment protocols using corticosteroids and interferon in
chronic liver diseases and their complications, much attention have been drawn to herbal remedies as
a last resort to help regenerating hepatocytes in liver fibrosis [4]. This notion was practically proven
by the sudden rise in the popularity and use of herbal drugs by liver patients (up to 65%) within few
years due to the fact that herbal remedies represent undoubtedly an easily accessible, affordable and
safe alternative to the current treatment protocols which turned out to be explicitly inadequate [4].
The genus Tamarix is native to Africa as well as the Eurasian region. The genus comprises over
50 species, including T. nilotica, which is an evergreen tree or shrub that can grow up to 5 m [5].
Tamarix nilotica has been widely incorporated in the folk medicine of many societies and cultures for
the treatment of sores, wounds, spleen oedema or uterus infections, while the extract itself has been
used as an antiseptic [6,7].
Former scientific reports proved that T. nilotica flowers possess in vivo hepatoprotective
properties [8], which inspired this study to compare the antifibrotic activity of the alcohol soluble
fraction of an aqueous extract of T. nilotica aerial parts from two different habitats, Egypt (ETN) and
Saudi Arabia (STN), and their secondary metabolite profiling using HPLC/HRESI/MS/MS.
2. Results
2.1. Polyphenols Metabolic Profiling
Chemical investigation of the alcohol soluble fraction of aqueous extract of ETN and STN was
conducted via HPLC/HRESI/MS/MS and dereplication tools using natural product databases and
comparison with the reported literature. Results (Tables 1 and 2) revealed that both fractions feature the
abundance of polyphenol secondary metabolites including flavonoid glycosides, methylated flavonoid
aglycones, phenylpropanoids, together with different sulphated compounds.
The negative ion mode profile of ETN showed three major peaks corresponding to methyl ferulate
sulphate, (iso)ferulic acid-3-sulphate and coniferyl alcohol sulphate derivative. The [M − H] peak at
m/z 287 and a fragment ion at m/z 207 corresponding to the removal of a −SO3 group were consistent
with those reported for methyl ferulate -3-O-sulphate [9]. Isoferulic acid-3-sulphate was identified
by its [M − H]− peak at m/z 273 and a base peak signal at m/z 193 for the deprotonated phenolic
acid [10]. Coniferyl alcohol 4-O-sulphate showed [M − H]− peak at m/z 259 and a fragment ion at
m/z 179 after the loss of its −SO3 group [11]. The chromatogram further showed a molecular ion peak
at m/z 299 along with fragment ion at m/z 284 as a result of the loss of a −CH3 group assigned for
kaempferide [9]. Gallic acid was identified after showing a peak at m/z 169 and a fragment at m/z 125
as described by [12,13]. A molecular ion peak at m/z 483 with fragment ion at m/z 313 due to loss of a
galloyl moiety proved the existence of nilocitin [14].
Kaempferol 7,4′ dimethyl ether 3-O-sulphate was identified by a peak at m/z 393 and a
fragment ion at m/z 313 indicating desulphonation [15]. A peak of the deprotonated ion at m/z 315
accompanied by a fragment ion at m/z 300 due to demethylation were similar to those reported for
tamarixetin [9,16,17]. Kaempferol showed a molecular ion peak at m/z 285 [15,18]. Another peak
at m/z 193 corresponding to deprotonated isoferulic acid showing a base peak at m/z 178 after the
loss of a methyl group was detected [17,19]. Quercetin was identified by a molecular ion peak at
m/z 301 [15,18]. A [M − H]− peak at m/z 197 representing methyl gallate 4-methyl ether showed
fragments at m/z 182 and 167 indicating successive demethylations [15,18]. Another peak appeared at
m/z 461 corresponding to kaempferol 3-O-β-glucronide with a daughter ion fragment at m/z 285 that
belongs to the deprotonated free aglycone [15].
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Table 1. Characterization of metabolites from ETN by HPLC-MS/MS in negative ion mode.
# Rt (Min) [M − H]− Error (ppm) MS/MS Fragment Formula Identity References
1 3.9 169.0220 −2.9 125.1086 C7H6O5 Gallic acid [12,13]
2 4.12 301.0421 1.6 273.0435, 179.0096, 150.9980 C15H10O7 Quercetin [15,18]
3 6.59 483.0859 −1.2 331.1573, 313.1711, 169.1114 C20H20O14 di-Galloyl-glucose (nilocitin) [14]
4 14.72 285.0469 2.8 239.0530, 143.1847 C15H10O6 Kaempferol [15,18]
5 28.09 197.0531 −1.5 183.2035, 182.1017, 168.1108, 167.1539 C9H10O5 Methyl gallate methyl ether [14]
6 30.61 259.0356 −0.8 229.0872, 179.0628, C10H12O6S Coniferyl alcohol sulphate [11]
7 36.82 193.0574 2.6 178.1750, 149.1777, 134.0983 C10H10O4 Ferulic acid isomer [17,19]
8 42.4 477.1101 2.1 315.0990, 300.1015 C22H22O12 Methylquercetin hexoside (tamarixetin-3-O-hexoside) [16]
9 43.93 273.0145 0.7 229.0810, 193.1538, 178.0940 C10H10O7S Ferulic acid sulphate derivative [10]
10 53.62 314.1315 −0.32 177.0162, 164.1282, 145.1110 C18H19NO4 n-Feruloyltyramine * [20,21]
11 57.08 287.0299 1.4 272.1937, 207.1997, 192.1747 C11H12O7S Methyl ferulate sulphate [9]
12 58.3 461.0806 −1.7 285.1083, 257.3536 C21H18O12 Kaempferol glucuronide [15]
13 67.53 315.0587 −1.3 300.1302, 193.1954 C16H12O7 Methylquercetin (tamarixetin) [9,16,17]
14 71.19 299.0624 3 284.1601, 271.2777 C16H12O6 Methylkaempferol (kaempferide) [9]
15 74.7 395.0154 −0.8 315.1095, 300.2426, 217.0871 C16H12O10S Methylquercetin-sulphate (tamarixetin sulphate) [11,17]
16 75.12 379.0195 1.8 299.1220, 284.2777 C16H12O9S Kaempferol methyl ether sulphate [11]
17 75.89 393.0366 −2 313.1219, 298.0152, 283.8303 C17H14O9S Kaempferol dimethyl ether sulphate [15]
* Detected only through inspection of the positive ion mode. ETN is the alcohol soluble fraction of aqueous extract of T. nilotica from Egypt.
Table 2. Characterization of metabolites from STN by HPLC-MS/MS in negative ion mode.
# Rt (Min) [M − H]− Error (ppm) MS/MS Fragment Formula Identity References
1 3.97 169.0213 1.18 125.1079 C7H6O5 Gallic acid [12,13]
2 4.17 301.0425 0.33 273.0441, 179.0084, 150.9916 C15H10O7 Quercetin [15,18]
3 6.47 483.0851 0.41 331.1561, 313.1709, 169.1116 C20H20O14 di-Galloylglucose (nilocitin) [14]
4 14.79 285.0483 −2.10 239.0536, 143.1841 C15H10O6 Kaempferol [15,18]
5 28.13 197.0533 −2.52 183.2027, 182.1022, 168.1119, 167.1531 C9H10O5 Methyl gallate methyl ether [14]
6 30.45 259.0351 1.15 229.0876, 179.0632 C10H12O6S Coniferyl alcohol sulphate [11]
7 43.98 273.0151 −1.46 229.0806, 193.1527, 178.0947 C10H10O7S Ferulic acid sulphate derivative [10]
8 53.72 314.1319 −1.60 177.0161, 164.12874, 145.1103 C18H19NO4 n-Feruloyltyramine * [20,21]
9 56.93 287.0301 0.69 272.1925, 207.2002, 192.1733 C11H12O7S Methyl ferulate sulphate [9]
10 58.20 461.0795 0.65 285.1096, 257.3548 C21H18O12 Kaempferol glucruonide [15]
11 67.77 315.0589 −1.90 300.1311, 193.1967 C16H12O7 Methyl-quercetin (Tamarixetin) [9,16,17]
12 71.17 299.0629 1.33 284.1607, 271.2769 C16H12O6 Methyl-kaempferol (Kaempferide) [9]
13 74.65 395.0159 −2.02 315.1085, 300.2417, 217.0865 C16H12O10S Methyl-quercetin-sulphate (Tamarixetin-sulphate) [11,17]
14 75.14 379.0191 2.89 299.1221, 284.2782 C16H12O9S Kaempferol-methyl ether-sulphate [11]
15 75.60 393.0368 −2.54 313.1212, 298.0147, 283.8312 C17H14O9S Kaempferol-dimethyl ether-sulphate [15]
* Detected only through inspection of the positive ion mode. STN is the alcohol soluble fraction of aqueous extract of T. nilotica from Saudi Arabia.
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Further examination revealed the presence of 4′-O-methyl quercetin 3-O-β-hexoside, identified
by a [M − H]− peak at m/z 477 and a base peak at m/z 315 due to cleavage of the O-glycosidic
bond release of the free aglycone and loss of the sugar moiety and another fragment at m/z 300
representing demethylation [16]. Kaempferol 4′-methyl ether 3-O-sulphate was characterized by a
molecular ion peak at m/z 379, and the removal of the −SO3 moiety was responsible for the base peak
at m/z 299 [11]. Finally, tamarixetin 3-O-sulphate was identified by a peak at m/z 395 and a base peak
at m/z 315 representing the loss of the −SO3 group [11,17]. n-Feruloyltyramine was only detected
through inspection of the positive ion mode showing a major peak of [M + H]+ at m/z 314 and a
fragment at m/z 177 that represents the loss of ferulic aldehyde [20,21].
Quantitative differences in the polyphenol profiles of ETN and STN were proved, where
kaempferol 4′-methyl ether 3-O-sulphate, methyl ferulate-3-O-sulphate, isoferulic acid-3-sulphate and
tamarixetin 3-sulphate were the major polyphenols of the STN extract.
2.2. Total Phenolic Content
The total phenolic contents of ETN and STN were determined through a calibration curve using
gallic acid as a standard. The results (Table 3) are presented in equivalent milligrams of gallic acid per
1.0 g of dried extract and they revealed that STN possesses a relatively higher total phenolic content
(111.8 mg GA/g extract) compared to ETN (95.1 mg GA/g extract).
Table 3. Total phenolic content of ETN and STN.
Total Phenolic Content (mg GA/gm Dry Extract)
ETN 95.1
STN 111.8
2.3. Oxygen Radical Absorbance Capacity (ORAC Assay)
The antioxidant activities of ETN and STN were tested by the ORAC assay using Trolox as a
positive control. Both extracts exhibited a pronounced antioxidant activity with ED50 values of 6.38
and 9.32 µg/mL, respectively, which are significantly lower than that of the reference standard Trolox
(ED50 = 27.0 µg/mL), (Figure 1).
Molecules 2018, 23, x FOR PEER REVIEW  5 of 20 
Molecules 2018, 23, x; doi: FOR PEER REVIEW  
 www.mdpi.com/journal/molecules 
Further examination revealed the presence of 4′-O-methyl quercetin 3-O-β-hexoside, identified 
by a [M − H]− peak at m/z 477 and a base peak at m/z 315 due to cleavage of the O-glycosidic bond 
release of the free aglycon  and loss of th  sugar moiety and another fragment at m/z 300 
representing demethylation [16]. Ka mpferol 4′-methyl ether 3 O-s pha e was characterized by a 
molecular ion peak at m/z 379, and the removal of the SO3 moiety w s responsible for the base peak 
at m/z 299 [11]. Finally, tamarixetin 3-O-sulphate was identified by a peak at m/z 395 and a base peak 
at m/z 315 representing the loss of the SO3 group [11,17]. n-Feruloyltyramine was only detected 
through inspection of the positive ion mode showing a major peak of [M + H]+ at m/z 314 and a 
fragment at m/z 177 that represents the loss of ferulic aldehyde [20,21].  
Quantitative differences in the polyphenol profiles of ETN and STN were proved, where 
kaempferol 4′-methyl ether 3-O-sulphate, methyl ferulate-3-O-sulphate, isoferulic acid-3-sulphate 
and tamarixetin 3-sulphate were the major polyphenols of the STN extract.  
2.2. Total Phenolic Content 
The total phenolic contents of ETN and ST  were determined throug  a calibration curve using 
gallic acid as a st ndard. The results ( able 3) are presented in equivalent milligrams of gallic acid 
per 1.0 g of dried extract and they revealed that STN possesses a relatively higher total phenolic 
content (111.8 mg GA/g extract) compared to ETN (95.1 mg GA/g extract).  
Table 3. Total phenolic content of ETN and STN.  
 Total Phenolic Content (mg GA/gm Dry Extract) 
E  95.1 
STN 111.8 
2.3. Oxygen Radical Absorbance Capacity (ORAC Assay) 
The antioxidant activities of ETN and STN were tested by the ORAC assay using Trolox as a 
positive control. Both extracts exhibited a pronounced antioxidant activity with ED50 values of 6.38 
and 9.32 µg/mL, respectively, which are significantly lower than that of the reference standard 
Trolox (ED50 = 27.0 µg/mL), (Figure 1). 
 
Figure 1. Radical scavenging activity of ETN and STN as compared to Trolox (as a positive control). 
Results are given as mean values ± SD of n = 3. 
Figure 1. Radical scavenging activity of ET and ST as compared to Trolox (as a positive control).
Results are given as mean values ± SD of n = 3.
Molecules 2018, 23, 1411 5 of 18
2.4. Hepatotoxicity Indices
The exposure to CCl4 caused a significant 3-fold increase in the serum AST and ALT levels
by when compared to the control group. Co-administration of silymarin with CCl4 significantly
lowered the AST and ALT levels near to the normal levels. Moreover, the concurrent administration
of ETN with CCl4 caused a dose related decrease in the levels of the AST and ALT by 61% and 60%
respectively as compared to the CCl4 intoxicated group. Similarly, the simultaneous administration of
the hydro alcoholic extract of STN with CCl4 caused a dose related lowering in the levels of the AST
and ALT by 60% and 58% respectively in comparison with the CCl4- challenged group. Remarkably,
the treatment of the rats with the ETN or STN extract alone caused a significant decline in the AST and
ALT concentrations as compared to the control group (Figure 2).
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Figure 2. Effect of ETN and STN on ALT (Panel A) and AST (Panel B) serum activities in rats subjected
to chronic CCl4 intoxication. * Data are the mean± SD (n = 10). a or b Significantly different from control
or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
2.5. Histopathological Examination with Hematoxylin and Eosin (H and E) Stain
Liver sections taken from the control group stained with H&E displayed a normal histological
structure of the central vein and surrounding hepatocytes with no histopathological alterations
(Figure 3A). Treatment with ETN or STN only didn’t exhibit any change in the normal liver architecture
(Figure 3F,I). Exposure to CCl4 triggered a thickening and fibrosis with fat cells deposition in the
hepatic capsule associated with extended fibrosis to the hepatic parenchyma between the degenerated
hepatocytes, in addition to the portal area that showed also fibrosis which was extended to the
parenchyma between the degenerated hepatocytes with inflammatory cells infiltration and congestion
in the portal vein (Figure 3B). The rats concurrently treated with silymarin showed restoration of
normal histological structure (Figure 3C). Animals co-treated with ETN (100 mg/kg) presented a mild
congestion in the central vein (Figure 3D), while ETN lower dose showed portal vein congestion with
inflammatory cells infiltration in the portal area (Figure 3E). On the other hand, groups co-administered
STN (100 mg/kg) showed only focal infiltration with inflammatory cells (Figure 3G), while STN
co-treatment (50 mg/kg) revealed diffuse cell infiltration with hepatocellular degeneration (Figure 3H).
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Figure 3. Representative photomicrographs of liver sections stained ith (H&E) (100×). (A) Section
taken from a control rat liver showing normal central vein and hepatic architecture; (B) Section
taken from rat liver exposed to CCl4 showing thickening and fibrosis with fat cells deposition in the
hepatic capsule associated with extended fibrosis to the hepatic parenchyma between the degenerated
hepatocytes (arrowhead); (C) Section taken from rat liver exposed to CCl4 and treated with silymarin
(100 mg/kg) showing restoration of normal histological structure; (D) Section taken from rat liver
exposed to CCl4 and treated with ETN (100 mg/Kg) showing mild congestion in the central vein;
(E) Section taken from rat liver exposed to CCl4 and treated with ETN (50 mg/Kg) showing portal
vein congestion with inflammatory cells infiltration in the portal area; (F) Section taken from rat liver
exposed only to ETN (100 mg/Kg) showing no histopathological alterations; (G) Section taken from rat
liver exposed to CCl4 and treated with STN (100 mg/Kg) showing focal inflammatory cells infiltration
(arrowheads); (H) Section taken from rat liver exposed to CCl4 and treated with STN (50 mg/Kg)
showing diffuse inflammatory cells infiltration (arrowheads), with hepatocytes degeneration. (I) Section
taken from rat liver exposed only to STN (100 mg/Kg) showing normal liver architecture.
2.6. Oxidative Stress Parameters
As hown in Figure 4A the CCl4 i i significantly reduced the GSH l vel by 50% as
compared to the control group. Conco it t ith silymarin and Cl4 off red a significant
protection against C l4 intoxicati si ific tly increasing the GSH level reaching 230% as
compared to the C l4 groups. Furthermore, animals treated with the ETN or STN extract along
with CCl4 showed an increase in the level of GSH by 147% and 328% respectively when compared to
group exposed to CCl4 in a dose related manner. Remarkably, the administration of the ETN or STN
alone revealed a significant increment in the level of GSH reaching 214% and 185% in comparison to
the control group.
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Lipid peroxidation measured as malondialdehyde (MDA) concentration showed a significant
3-fold increase as a result of CCl4 administration, as compared to the control group. The administration
of silymarin in tandem with CCl4 exhibited a significant inhibition in the rise of MDA level and kept it
within the normal values when compared to the control. Moreover, animals treated with the ETN or
STN extract in addition to CCl4 showed a dose related reduction in the level of MDA by 42% and 54%
respectively when compared to CCl4 intoxicated group. On the other hand, there was no significant
change in the lipid peroxidation when the animals were administered the ETN or STN extract alone in
comparison with the control group (Figure 4B).
Intoxication with CCl4 brought an evident reduction in the catalase activity by 62% as compared to
the control group. Treatment of animals with silymarin concomitantly with CCl4 triggered significant
increased the catalase activity level to reach 248% as compared to the CCl4-exposed group. Moreover,
animals treated by ETN or STN extract along with CCl4 exhibited a dose related increase in the
activity of catalase reaching 200% and 224% respectively when compared to group exposed to CCl4.
Interestingly The administration of the ETN or STN alone revealed a significant raise in the catalase
activity by 88% and 81% after comparison with the control group (Figure 4C).
2.7. iver ibrosis arkers
i er fibrosis was assessed biochemically b determining collagen accumulation indices in terms
of its main co ponent, hydroxyproline. Measurement of hydroxyproline assured the histological
observation of enhanced liver fibrosis by CCl4. As the liver hydroxyproline content in the CCl4
c allenged group was 513% as compared to the control group. The animal treatment with silymarin
together with CCl4 significantly lowered the hydroxyproline conte t in liver by 73% with respect
to the CCl4 exposed group. Moreover, animals treated with the ETN or STN extract in addition to
CCl4 showed a dose related significant reduction in the level of liver hydroxyproline by 64% and 71%
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respectively when compared to CCl4 intoxicated group. On the other hand, there was no significant
alteration in the hydroxyproline liver content when the animals were administered the ETN or STN
extract alone in comparison with the control group (Figure 5).
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Figure 5. Effect of ETN and STN on liver hydroxyproline content rats subjected to chronic CCl4
intoxication. * Data are the mean ± SD (n = 6). a or b: Significantly different from control or CCl4 group
respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
i s i al y in the C l4 exposed group as shown by the intense brown staining nd optical density
(O.D) of 127% with respect o the control group (Figure 6B). Animals co-treated with silym rin, ETN
or STN extract markedly attenuated this elevated expre sion (Figure 6C–E) which was assured by
lowering the O.D to 83%, 80% and 77% as compared to the CCl4 exposed group.
2.8. Inflammatory Markers
The measurement of the TNF-α and COX-2 content was carried out using ELISA technique.
Exposure to CCl4 caused a significant rise in the TNF-α value by 133% with respect to the control
group. The concurrent treatment with silymarin, ETN or STN suppressed the rise in the TNF-α by
53%, 42.5% and 42% respectively, in comparison with the CCl4 challenged group (Figure 7A).
The COX-2 levels showed a similar pattern to that of TNF-α by a 3-fold increase in the
COX-2 concentration upon exposure to CCl4.The effect of the intoxication was ameliorated by
co- administration of silymarin, ETN or STN that reduced the COX-2 level to 41%, 43% and 35%
respectively, as compared to the group intoxicated with CCl4 (Figure 7B).
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Exposure to CCl4 caused a significant rise in the TNF-α value by 133% with respect to the control 
Figure 6. Expression of alpha smooth muscle actin (α-SMA) by immunohistochemical staining (×100).
(A) Photomicrograph of liver section of control rats showing minimal immunostaining for α-SMA;
(B) Photomicrograph of liver section of CCl4 intoxicated rats showing extensive α-SMA expression of as
shown by the intense brown staining; (C) Photomicrograph of liver section of (CCl4/Silymarin) treated
rats showing li ited α-SMA expression; (D) Phot micrograph of liver section rats concurrently
treated with CCl4 (1 mL/kg) twice a week and ETN (100 mg/kg) three times per week, showing
limited α-SMA ex ression; (E) Ph tomicrograph of liver secti n of rats simultaneously treated with
CCl4 (1 mL/kg) twice a week and STN (100 mg/Kg) three times per week, showing minimal α-SMA
expression; (F) A graphical representation of the α-SMA expression as optical density (O.D) for the
liver sections from different groups, where a or b express the significant difference from control or CCl4
group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
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Figure 7. Effect of ETN and STN aqueous alcohol extracts on hepatic TNF-α (Panel A) and COX-2
content (Panel B) in rats subj cted to chronic Cl4 intoxication. * Data are the mean ± SD (n = 6). a or
b: Significantly different from control or CCl4 group respectively at p < 0.05 using ANOVA followed by
Tukey-Kramer as a post-hoc test.
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NF-κB was assessed immunohistochemically by detecting the activated subunit p65 in liver
tissues. Control rats showed a minimal immunostaining for NF-κB (Figure 8A). CCl4 brought an
increase in the p65 content in the liver tissues, which was manifested by the intense brown staining
that was proven by the significant increase in OD by 33% (Figure 8B). However, silymarin significantly
lowered the expression of NF-κB as well as the OD by 19% with respect to the CCl4-challenged group.
In addition, co-treatment of rats with ETN or STN significantly reduced the expression of NF-κB,
which was assured by the reduction in the OD by 12% and 16%, respectively, when compared to
CCl4-intoxicated group (Figure 8D,E).Molecules 2018, 23, x FOR PEER REVIEW  12 of 20 
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Figure 8. Expression of nuclear factor kappa B (NF-κB) by immunohistochemical staining (100×).
(A) Photomicrograph of liver section of control rats showing minimal immunostaining for NF-κB;
(B) Photomicrograph of liver section of CCl4 intoxicated rats showing increased NF-κB expression of as
shown by the intense brown staining; (C) Photomicrograph of liver section of (CCl4/silymarin) treated
rats showing limited NF-κB expression; (D) Photomicrograph of liver section of rats concurrently
treated with CCl4 (1 mL/Kg) twice a week and ETN (100 mg/Kg) three times per week, showing
limited NF-κB expression; (E) Photomicrograph of liver section of rats simultaneously treated with
CCl4 (1 mL/Kg) twice a week and STN (100 mg/Kg) three times per week, showing decreased NF-κB
expression; (F) A graphical r presentation of the NF-κB expression as optical density (O.D) for the liver
sections from differe t gr ups, where a or b express the significant difference from c ntrol or CCl4
group r spectiv ly at p < 0.05 using ONE-WAY ANOVA followed by Tukey-Kramer as a post-hoc test.
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3. Discussion
The aim of current study was to explore the metabolite profile of the alcohol soluble fraction
of T. nilotica aqueous extracts (ETN and STN), assess in vivo antifibrotic activity and the possible
underlying mechanism. HPLC/HRESI/MS/MS profiling of ETN and STN highlighted the presence of
various polyphenol derivatives, which played an important role in the antioxidant and antifibrotic
activities. Interestingly, sulphated polyphenols represented the main components of STN in
comparison to ETN. This finding is due to the fact that, same species growing in different geographical
locations is subjected to variations due to their occurrence in contrasting ecological and environmental
conditions [22]. Despite the fact that both ETN and STN exhibited potential antifibrotic activity;
the results displayed a significant GSH elevation in animal groups treated with STN when compared to
that treated with ETN or even the control rats. This could be referred to the high content of sulphated
polyphenols present in STN, which assure the fact reported earlier that the intake of sulphated
polyphenols significantly influence GSH synthesis [23]
Polyphenols are well-known for their antioxidant and anti-inflammatory properties on both
in vitro and in vivo experimental models [24]. Accumulating evidence shows that inflammation—in
addition to increased oxidative stress—plays an important role in the development of different liver
diseases including fibrosis [25]. According to the current and former study results, T. nilotica is reported
as a rich source of various polyphenol compounds [26]. In the present study, the ORAC assay results
stand in line with the calculated total phenolic content, showing that the radical scavenging capacity
of ETN and STN fractions could be a result of the high phenolic content of both extracts.
Concerning the antifibrotic activity, ETN and STN were investigated against CCl4-induced
fibrosis in rats. In this regard, CCl4 is considered as one of the most regularly used hepatotoxins
in the experimentally-induced liver diseases in animals [27]. Its hepatotoxic effect is initiated by
cytochrome P450 2E1 that converts CCl4 to the highly reactive trichloromethyl radical (CCl3·) which is
afterward transformed into more destructive trichloromethyl peroxy radical (CCl3OO·) in the presence
of oxygen [28]. The generated free radicals cause injury of hepatocellular membrane via depleted
GSH content, increased lipid peroxidation, and release of inflammatory mediators from activated
inflammatory cells that in turn potentiate CCl4-induced hepatic injury [29].
In the present study, CCl4 caused a significant elevation in serum ALT and AST, indicating
hepatocellular inflammation and necrosis [30]. Co-treatment of animals with ETN or STN significantly
alleviated such progressive hepatic changes. Silymarin was used as a standard antifibrotic agent due
to its well-known hepatoprotective ability [31]. These effects were further proven by histopathological
examination of the CCl4 animals co-treated with the extract or silymarin, which presented minimal
hepatic tissues disfiguring as compared to the CCl4-exposed rats.
Lipid peroxidation (measured as MDA) is recognized as one of the principal steps of CCl4-induced
liver injury, as a result, the antioxidant activity is a very important property in a hepatoprotective agents.
In fact, MDA has been used for a long time as a biomarker of oxidative stress [32,33]. The increase of
MDA reflects enhanced lipid peroxidation and tissue injury. Catalase (a tetrameric heme protein), is one
of the major intracellular antioxidant enzymes. Its function is to protect cells from the accumulation
of H2O2 by catalyzing its decomposition into water and oxygen [34]. The reduced catalase (CAT)
activity is a proof for compromised enzymatic protection against tissue damage caused by elevated
oxidative stress. In contrast, GSH represents the non-enzymatic part of the host antioxidant defense
mechanism. It can effectively scavenge free radicals, while being oxidized by glutathione peroxidase
into glutathione disulfide which can be reduced back to GSH by glutathione reductase with the
consumption of NADPH [35]. GSH can also react with various electrophiles, physiological metabolites
and xenobiotics to form mercapturates, which are catalyzed by other antioxidant enzymes.
In this study, there was a marked increase in MDA with concomitant decrease in GSH and CAT
activity after chronic CCl4 challenge. However, ETN and STN extracts and standard silymarin kept the
MDA levels close to or within the normal values. In another context, ETN, STN and silymarin triggered
a significant increase in the CAT activity making it closer to the normal values. As for the GSH content,
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the silymarin and ETN prevented its consumption, while STN significantly raised the GSH level even
above control which could count for the STN efficient antioxidant activity. The observed results are
in agreement with earlier studies that showed that several antioxidants possess potential protective
effects against CCl4 induced liver fibrosis [36,37].
Interestingly, NF-κB is a transcriptional regulator of genes involved in immunity, inflammatory
response, cell fate, and function [38]. Kupffer cells display powerful NF-κB activation in response
to liver injury by CCl4 and the oxidative damage. This results in production and secretion of
proinflammatory cytokines such as TNF-α which is strongly implicated as a fibrosis promoter [39].
Accordingly, the persistent elevation in the levels of NF-κB promote the secretion of inflammatory
and chemotactic factors in hepatocytes and thereby worsen hepatic inflammation and fibrosis [40].
In this context, several studies showed that downregulation of NF-κB expression and subsequent
inflammatory cascade is capable of alleviating CCl4-induced hepatic fibrogenesis [41,42]. Of the
various kinds of inflammatory mediators TNF-α plays an important role in the pathogenesis of
liver fibrosis through activation of Kupffer cells. TNF-α stimulates the release of cytokines from the
macrophages and induces phagocyte oxidative metabolism [43]. Thus, a vicious cycle is established
in the hepatocytes: TNF-α promotes NF κB activation, and NF-κB leads to enhanced production
of additional TNF-α. This cycle eventually alters the structure of the hepatocytes, and impairs
their function, consequently, prolonged activation of NF-κB leads to perpetuated inflammatory
responses [44]. Moreover, the upregulation of COX-2 has been demonstrated in human liver cirrhosis
as a result of active inflammation [45,46]. In the current study, the administration of silymarin, ETN
and STN concomitantly with CCl4 significantly reduced the expression of NF-κB and hence inhibited
the downstream inflammatory cascade as evidenced by the significant inhibition of the augmented
hepatic levels of TNF-α and COX-2 demonstrating the satisfactory anti-inflammatory properties of
the extracts.
Hydroxyproline is one of the sensitive markers that significantly rises during fibrosis reflecting
the increase in the synthesis of collagen [47]. In addition to collagen, expression of the microfilament
protein “α-SMA” has been explored as a marker for activation hepatic stellate cells and hence hepatic
fibrosis [48]. In this study, there was a significant increase in the hydroxyproline content associated with
α-SMA overexpression due to CCl4 exposure. Co-administration of ETN, STN or silymarin offered a
decrease in the hydroxyproline level along with reduction in the α-SMA expression. It is important to
note that all of the effects caused by the co-treatment with ETN or STN were dose dependent.
From the available results, it could be concluded that the ETN and STN presents a significant
in vivo dose related antifibrotic activities, which in turn may be due to the polyphenols content.
The underlying mechanism could be—at least partly—due to restraining of the oxidative stress through
GSH replenishment along with inhibiting the inflammatory response. These findings stands in line
with previous reports that confirms the antifibrotic activity of quercetin [49,50], kaempferol [51], gallic
acid [52] or falvonoids [53]. In addition to the earlier report which refer the in vivo hepatoprotective
properties of T. nilotica flowers to its phenolic constituents [8].
4. Materials and Methods
4.1. Materials
The aerial parts of T. nilotica were collected from the campus of the German University (Cairo,
Egypt) and from Al-Taif Mountain (Saudi Arabia) in March, 2015. Both plants were collected
at the flowering stage. The authenticity of the species was confirmed by Dr. Mohamed El
Gebaly (Professor of Taxonomy at the National Research Center, Egypt). A voucher specimen was
deposited at the Herbarium of Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams
University, Egypt. Sample was kept under voucher number PHG-P-TN194. Ellman’s reagent
[5,5-dithio-bis(2-nitrobenzoic acid); DTNB], reduced glutathione (GSH), bovine serum albumin,
chloramine-T, p-dimethylaminobenzaldehyde (PDMA), hydroxyproline, and thiobarbituric acid (TBA)
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were purchased from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). Carbon tetrachloride (CCl4),
n-butanol, dipotassium hydrogen phosphate (K2HPO4), potassium dihydrogen phosphate (KH2PO4)
and trichloroacetic acid (TCA) were obtained from Al-Gomhoryyah Chemical Co. (Cairo, Egypt).
4.2. Animals
Animal experiments were conducted in accordance with the ethical guidelines of Ain Shams
University (Cairo, Egypt). Male albino rats (100–150 g) were obtained from Nile Co. for Pharmaceutical
and Chemical Industries (Cairo, Egypt). Rats were housed in an air-conditioned atmosphere, at a
temperature of 25 ◦C with alternatively 12 h light and dark cycles. Animals were acclimatized for
2 weeks before performing the study. They were kept on a standard diet and water ad libitum. Standard
diet pellets (El Nasr, Cairo, Egypt) contained not less than 20% protein, 5% fiber, 3.5% fat, 6.5% ash and
a vitamin mixture. Animal care and experimental design were approved and conducted in accordance
with the guidelines approved by the Research Ethics Committee, Faculty of Pharmacy, Ain Shams
University, Egypt. (#00146/15).
4.3. Plant Extraction
Tamarix nilotica aerial parts (750 g) from Egypt and Saudi Arabia were exhaustively extracted with
distilled water at 25 ◦C with stirring (2 L × 3), individually. Each extract was dried at 40 ◦C under
vacuum followed by alcohol extraction. The alcohol soluble fractions of aqueous extracts were dried
under vacuum to yield 40.36 g and 44.71 g or residue, respectively. The alcohol soluble fraction of
aqueous extract of Saudi T. nilotica (STN) and Egyptian T. nilotica (ETN) were subjected to further
analysis by HPLC/HRESI/MS/MS.
4.4. Phenolic Content
The total phenolic content of the extract was assessed through Folin–Ciocalteu method [54].
A volume of 200 µL of crude extract (1 mg/mL) were diluted with distilled water to 3 mL then mixed
thoroughly with 0.5 mL of Folin–Ciocalteu reagent for 3 min, followed by the addition of 2 mL of
20% (w/v) anhydrous sodium carbonate. The mixture was allowed to stand for 60 min in the dark,
and absorbance was measured at 765 nm. The calculation of the total phenolic content was done using
gallic acid as a standard via calibration curve with a straight line equation (y = 0.0012x + 0.5958) and
regression correlation (R2 = 0.9994). Results (Table 3) are presented in equivalent milligrams of gallic
acid per 1.0 g of dried extract. All assays were carried out in triplicates [55].
4.5. LC–HRESI-MS–MS Analysis
The chromatographic analysis was performed on an Agilent 1200 series HPLC instrument (Agilent
Technologies, Santa Clara, CA, USA), the column was a Gemini 3 µm C18 110 Å (Phenomenex, Torrance,
CA, USA), with dimensions 100 × 1 mm i.d., protected with a RP C18 100 Å guard column with
dimensions 5 mm × 300 µm i.d., 5 µm. The mobile phase components were 2% acetic acid (A) and
90% MeOH, 2% acetic acid (B) at a flow rate of 50 µL/min. The mobile phase gradient was: 0–60 min,
5% B; 60–70 min, 50% B; 70–80 min, 90% B; 80–90 min, 5% B. The samples were dissolved in 5% MeOH
and 2% acetic acid with a concentration of 1 mg/mL then filtered using a syringe filter with a pore
size 0.2 µm. The sample injection volume was 10 µL. A Fourier transform ion cyclotron resonance
(FTICR) mass analyzer was used equipped with an electrospray ionization (ESI) system and controlled
by Xcalibur® software. Detection was performed in the negative and positive ion modes applying a
capillary voltage of 36 V and a temperature of 275 ◦C. The API source voltage was adjusted to 5 kV,
and the desolvation temperature to 275 ◦C. Nitrogen was used as a nebulizing gas with a flow adjusted
to 15 L/min. The analytical run time was 89 min and the full mass scan covered the mass range from
150 to 2000 m/z with resolution of 100,000 [55]. Quantitation by LC-MS-MS; the absolute area and area
percent of each peak was calculated by Xcalibur® software with ICIS peak algorithm then exported to
Microsoft Excel® software for preparation of graphs and further data analysis.
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4.6. Oxygen Radical Absorbance Capacity (ORAC Assay)
Experiments were performed as previously described in black 96-well plates [56]. In each well
of a 96-well plate, 150 µL fluorescein (final concentration: 2.5 nM), 25µL Trolox (final concentrations:
0.78–25 µM) or 25 µL tested samples were pipetted in quadruplicate. Plate was allowed to equilibrate
at 37 ◦C for 30 min. After this time, fluorescence measurements (Ex. 485 nm, Em. 520 nm) were
taken every 90 s; first to determine the background signal. After three cycles 25 µL AAPH (final
concentration: 60 mM) were added manually in each well with a multi-channel-pipette. Measurements
were taken as quickly as possible since the ROS generator displays immediate activity after addition.
Fluorescence measurements were continued for 90 min. Half-life time of fluorescein was determined
using the MS Excel software.
4.7. In-vivo Experimental Design
Animals were classified randomly into nine groups (ten animals per group) and treated for six
weeks as follows; Group 1: Rats were given corn oil three times per week and considered as control
animals; Group 2: Rats were given CCl4 (1 mL/kg, 1:1 mixture with corn oil, i.p.), twice weekly to
induce liver fibrosis [57]; Group 3: Rats were given CCl4 (1 mL/kg, 1:1 mixture with corn oil, i.p.) twice
weekly and silymarin oral suspension (100 mg/kg, suspended in distilled water), three times per week
at alternating days with CCl4 and considered as a positive control; Group 4: Rats were given CCl4
(1 mL/kg, 1:1 mixture with corn oil, i.p.) twice weekly and ETN extract (100 mg/kg, orally, dissolved
in distilled water), three times per week at alternating days with CCl4; Group 5: Rats were given CCl4
(1 mL/kg, 1:1 mixture with corn oil, i.p.) twice weekly and ETN extract (50 mg/kg, orally, dissolved in
distilled water), three times per week at alternating days with CCl4; Group 6: Rats were given ETN
extract alone (100 mg/kg, orally, dissolved in distilled water) three times per week; Group 7: Rats
were given CCl4 (1 mL/kg, 1:1 mixture with corn oil, i.p.) twice weekly and STN extract (100 mg/kg,
orally, dissolved in distilled water), three times per week at alternating days with CCl4; Group 8: Rats
were given CCl4 (1 mL/kg, 1:1 mixture with corn oil, i.p.) twice weekly and STN extract (50 mg/kg,
orally, dissolved in distilled water), three times per week at alternating days with CCl4; Group 9: Rats
were given STN alone (100 mg/kg, orally, dissolved in distilled water) three times per week.
At the end of the sixth week, the rats were anaesthetized and blood samples were collected from
the retro-orbital plexus and allowed to clot. Serum was separated by centrifugation at 1000 rpm for
10 min and used for the assessment of liver functions. Then, rats were sacrificed and liver tissues were
dissected, weighed and washed with ice-cold saline. Then livers were then homogenized in ice-cold
saline using a homogenizer to obtain 20% homogenate. Aliquots of the liver homogenate were stored
at −80 ◦C prior to biochemical analysis. In addition, specimens from the three major lobes of each liver
were fixed in 10% formalin saline for histopathological and immunohistochemical investigations.
4.8. Assessment of Hepatotoxicity Indices
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined
according to the procedure previously reported [57].
4.9. Assessment of Oxidative Stress Markers
For evaluating GSH reserves, 0.5 mL of the homogenate was added to a tube with 0.5 mL of
10% TCA. For 15 min, the tubes were shaken moderately and intermittently, then a centrifugation at
3000 rpm for 10 min was done. An aliquot of the formed supernatant (0.2 mL) was added to a tube
containing 0.1 mL Ellman’s reagent and 1.7 mL phosphate buffer, then the absorbance was read at
412 nm within 5 min [58]. The results were expressed as mmol of GSH/mg protein. Lipid peroxidation
was measured by calculating the level of thiobarbituric acid reactive substances (TBARS) measured as
malondialdehyde (MDA), as per the method of [59]. The reaction was prepared by addition of 0.5 mL
of the homogenate to 1.0 mL 0.6% TBA and 2.5 mL of 20% TCA, and then the mixture was heated in a
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boiling water bath for 20 min followed by cooling and addition of 4 mL n-butanol along with shaking.
Separation of the alcohol layer was done by 10 min centrifugation at 2000 rpm for and absorbance
was measured at 535 nm. The results were expressed as nmole of MDA/mg protein using 1,1,3,3-
tetraethoxypropane used as standard. In addition, CAT activity was assessed using commercially
available biochemical kit (Biodiagnostics, Cairo, Egypt).
4.10. Assessment of Liver Fibrosis
Liver fibrosis was evaluated using two different markers: hydroxyproline and α-SMA. The first
one was determined according to previously described method [60]. The procedure utilized a volume
of 0.5 mL of 20% liver homogenate which was kept in 1 mL of 6 M HCl for 8 h at 120 ◦C. A portion of
the digested homogenate (25 µL) is added to 25 µL citrate-acetate buffer then 500 µL of chloramine
T solution was added and finally the mixture is kept for 20 min at room temperature. Then, 500 µL
Ehrlich’s solution was added and the mixture is incubated at 65 ◦C for 15 min. After cooling for
10 min, the color developed was spectrophotometrically measured at 550 nm. The results were
presented as µg/g of wet tissue. In addition, α-SMA expression in formalin-fixed paraffin-embedded
rat liver was assessed immunohistochemically using monoclonal antibody (MA1-744, ThermoFisher,
Loughborough, UK).
4.11. Assessment of Inflammatory Markers
The TNF-α and COX-2 levels in liver homogenate was performed using commercial ELISA
kit obtained from Sigma Aldrich Chemical Co. according to the manufacturer's instructions.
The quantities of TNF-α and COX-2 were expressed as ng/mg protein. The protein was calculated using
bovine serum albumin as standard [61]. Furthermore, NF-κBp65 subunit expression was assessed
immunohistochemically in formalin-fixed paraffin-embedded rat liver using polyclonal antibody
(PA5-16545, ThermoFisher).
4.12. Statistical Analysis
Data are presented as mean ± SEM, multiple group comparisons were carried out using one-way
analysis of variance (ANOVA) followed by the Tukey-Kramer test for post-hoc analysis. Probability
values of p < 0.05 were considered statistically significant. All statistical analyses were performed
using GraphPad InStat software, version 3.05 (GraphPad Software, Inc., La Jolla, CA, USA). Graphs
were sketched using GraphPad Prism software, version 5.00
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